WO2023122325A3 - Meta anilide compounds and methods for use of the same to treat diseases and disorders - Google Patents

Meta anilide compounds and methods for use of the same to treat diseases and disorders Download PDF

Info

Publication number
WO2023122325A3
WO2023122325A3 PCT/US2022/053923 US2022053923W WO2023122325A3 WO 2023122325 A3 WO2023122325 A3 WO 2023122325A3 US 2022053923 W US2022053923 W US 2022053923W WO 2023122325 A3 WO2023122325 A3 WO 2023122325A3
Authority
WO
WIPO (PCT)
Prior art keywords
meta
methods
disorders
same
treat diseases
Prior art date
Application number
PCT/US2022/053923
Other languages
French (fr)
Other versions
WO2023122325A2 (en
Inventor
Scott D. Larsen
Richard Neubig
Dylan KAHL
Original Assignee
Regents Of The University Of Michigan
Board Of Trustees Of Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Michigan, Board Of Trustees Of Michigan State University filed Critical Regents Of The University Of Michigan
Publication of WO2023122325A2 publication Critical patent/WO2023122325A2/en
Publication of WO2023122325A3 publication Critical patent/WO2023122325A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Disclosed herein are meta anilide inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, and methods for their use in treating or preventing diseases, such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are as described.
PCT/US2022/053923 2021-12-23 2022-12-23 Meta anilide compounds and methods for use of the same to treat diseases and disorders WO2023122325A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293335P 2021-12-23 2021-12-23
US63/293,335 2021-12-23

Publications (2)

Publication Number Publication Date
WO2023122325A2 WO2023122325A2 (en) 2023-06-29
WO2023122325A3 true WO2023122325A3 (en) 2023-08-03

Family

ID=86903654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/053923 WO2023122325A2 (en) 2021-12-23 2022-12-23 Meta anilide compounds and methods for use of the same to treat diseases and disorders

Country Status (1)

Country Link
WO (1) WO2023122325A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073847A2 (en) * 2014-11-07 2016-05-12 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
WO2019055590A1 (en) * 2017-09-13 2019-03-21 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
WO2019089729A1 (en) * 2017-10-31 2019-05-09 University Of Miami Kinase inhibitors for the treatment of central and peripheral nervous system disorders
WO2021071806A1 (en) * 2019-10-07 2021-04-15 D. E. Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073847A2 (en) * 2014-11-07 2016-05-12 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
US10662183B2 (en) * 2014-11-07 2020-05-26 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
WO2019055590A1 (en) * 2017-09-13 2019-03-21 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
WO2019089729A1 (en) * 2017-10-31 2019-05-09 University Of Miami Kinase inhibitors for the treatment of central and peripheral nervous system disorders
WO2021071806A1 (en) * 2019-10-07 2021-04-15 D. E. Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND ANONYMOUS : "N-(4-Chlorophenyl)-5,5-difluoro-1-[3-(2-pyridinyl)benzoyl]-3-piperidinecarboxamide", XP093083313, retrieved from PUBCHEM *

Also Published As

Publication number Publication date
WO2023122325A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
EA202191177A1 (en) 2-AMINO-N-HETEROARYLNICOTINAMIDES AS NAV1.8 INHIBITORS
MX2022012780A (en) Fused tricyclic kras inhibitors.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2020013570A (en) Purinone compounds and their use in treating cancer.
MX2022015581A (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors.
MX2023007192A (en) Prmts inhibitors.
MX2022015579A (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors.
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
MX2019000536A (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme.
MX2022015531A (en) Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof.
MX2018013325A (en) Adenine derivatives as protein kinase inhibitors.
CR20230519A (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CR20230362A (en) Cdk2 inhibitors and methods of using the same
AU2022367432A1 (en) Quinoline compounds as inhibitors of kras
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
WO2023122325A3 (en) Meta anilide compounds and methods for use of the same to treat diseases and disorders
MX2022009941A (en) Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors.
AU2022386486A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
AU2018276273A1 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
MX2023001618A (en) Heterocyclic compound as bcl-2 inhibitor.
MX2023007218A (en) Cocrystal of a cdk inhibitor.
MX2022001158A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy.
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.
MX2021012499A (en) Improved inhibitors of the notch transcriptional activation complex and methods for use of the same.
WO2018067638A3 (en) High mobility group b1 protein inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912519

Country of ref document: EP

Kind code of ref document: A2